Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
https://www.zacks.com/stock/news/2201371/should-ishares-msci-usa-min-vol-factor-etf-usmv-be-on-your-investing-radar?cid=CS-ZC-FT-style_box_etf-2201371
Dec 22, 2023 - Style Box ETF report for USMV
0
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
https://www.fool.com/investing/2023/12/21/weighing-their-chances-5-leading-healthcare-compan/?source=iedfolrf0000001
Dec 21, 2023 - Which weight-loss stocks are good buys today?
0
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
https://www.zacks.com/stock/news/2201005/3-cancer-focused-biotechs-that-appear-promising-bets-for-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2201005
Dec 21, 2023 - With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
0
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
https://www.fool.com/investing/2023/12/18/these-are-the-3-hottest-biopharma-trends-of-2024/?source=iedfolrf0000001
Dec 18, 2023 - 2024 is going to be a sizzler in the biopharma sector.
0
5 Big Drug Stocks That May Continue to Outperform in 2024
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
0
LLY Down as Patients Regain Weight After Stopping Zepbound
https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196988
Dec 12, 2023 - Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
0
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2195769/eli-lilly-lly-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2195769
Dec 08, 2023 - The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now?
https://www.zacks.com/stock/news/2193345/is-it-a-good-idea-to-invest-in-ac-immune-aciu-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2193345
Dec 05, 2023 - Here, we discuss some reasons why investing in AC Immune (ACIU) stock now may turn out to be a prudent move.
0
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug Jaypirca
https://www.zacks.com/stock/news/2193151/lilly-lly-gets-second-fda-nod-for-lymphoma-drug-jaypirca?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193151
Dec 04, 2023 - Following the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway.
0